Alnylam (ALNY) Pharmaceuticals announced that the European Commission has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy as an additional indication for its orphan RNAi therapeutic AMVUTTRA. The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis in adults
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook
- Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
- Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements
- Alnylam presents contemporary analysis of HELIOS-B Phase 3 study of vutrisiran
- Alnylam Pharma Re-elects Directors at Annual Meeting